US 9504730
Method of achieving a thymosin beta 4 concentration in a human patient
granted A61KA61K38/1709A61K38/32
Quick answer
US patent 9504730 (Method of achieving a thymosin beta 4 concentration in a human patient) held by REGENERX BIOPHARMACEUTICALS, INC. expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERX BIOPHARMACEUTICALS, INC.
- Grant date
- Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K38/1709, A61K38/32, A61P, A61P13/06